Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.51 |
| ▸ | FES | P07332 | 1/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.51 |
| ▸ | MARK3 | P27448 | 1/20 | 0.51 |
| ▸ | TYK2 | P29597 | 1/20 | 0.51 |
| ▸ | FLT4 | P35916 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | CLK2 | P49760 | 1/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25784651 | 0.86 | HDAC2 (0.61) | HDAC8HDAC2HDAC6KMT2AMEN1 | |
| SCHEMBL3558312 | 0.85 | MEN1 (0.63) | HDAC8HDAC2HDAC6KMT2AMEN1 | |
| SCHEMBL30208757 | 0.85 | MEN1 (0.63) | HDAC8HDAC2HDAC6KMT2AMEN1 | |
| SCHEMBL23222377 | 0.83 | HDAC2 (0.58) | HDAC8HDAC2HDAC6KMT2AMEN1 | |
| SCHEMBL16610103 | 0.83 | CYP3A4 (0.61) | HDAC8HDAC2HDAC6KMT2AMEN1 | |
| SCHEMBL2755854 | 0.83 | RECQL (0.71) | HDAC8HDAC2HDAC6KMT2AMEN1 | |
| SCHEMBL48869 | 0.83 | POLB (0.60) | HDAC8HDAC2HDAC6KMT2AMEN1 | |
| SCHEMBL427121 | 0.83 | RECQL (0.70) | KMT2ASMN1; SMN2RECQLFESRET | |
| SCHEMBL18317280 | 0.82 | FLT4 (0.70) | HDAC8HDAC2HDAC6KMT2AMEN1 | |
| SCHEMBL18317281 | 0.82 | FLT4 (0.75) | HDAC8HDAC2HDAC6KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753418-B2 | Compounds for the modulation of Myc activity | SYROS PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS INC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20220048927-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2022-02-17 | — | — | US | disclosed |
| US-11124527-B2 | Compounds for the modulation of Myc activity | SYROS PHARMACEUTICALS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210188833-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS INC (US) | 2021-06-24 | — | — | US | disclosed |
| US-10787444-B2 | Compounds for the modulation of myc activity | SYROS PHARMACEUTICALS, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20180354972-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-12-13 | — | — | US | disclosed |
| US-20180162851-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-06-14 | — | — | US | disclosed |
| WO-2016196910-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS, INC. (US) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016197078-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS, INC. (US) | 2016-12-08 | — | — | WO | disclosed |
| US-20120020920-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2206715-A1 | Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor | Japan Tobacco, Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-7659263-B2 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-02-09 | — | — | US | disclosed |
| EP-1719773-B1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20090036444-A1 | 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2009-02-05 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-1688420-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2006-08-09 | — | — | EP | disclosed |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | HDAC8 380/4885HDAC2 565/4885HDAC6 82/4885 |
| US-11753418-B2 | Compounds for the modulation of Myc activity | MYC, MYCBP, MYCBP2 | HDAC8 3242/4885HDAC2 4098/4885HDAC6 2305/4885 |
| US-20090036444-A1 | 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor | GTF3C5, ZC3HAV1, POLI | HDAC8 432/4885HDAC2 611/4885HDAC6 64/4885 |
| US-20180162851-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | MYC, MYCBP, MYCBP2 | HDAC8 3405/4885HDAC2 3970/4885HDAC6 2251/4885 |
| US-20220048927-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | MYC, MYCBP, MYCBP2 | HDAC8 3242/4885HDAC2 4098/4885HDAC6 2305/4885 |
| US-20120020920-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | GTF3C5, ZC3HAV1, POLI | HDAC8 432/4885HDAC2 611/4885HDAC6 64/4885 |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | TPMT, JAK2, GTF3C5 | HDAC8 2575/4885HDAC2 2025/4885HDAC6 1478/4885 |
| US-20210188833-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | MYC, MYCBP, MYCBP2 | HDAC8 3100/4885HDAC2 3395/4885HDAC6 1517/4885 |
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | MYC, MYCBP, MYCBP2 | HDAC8 3100/4885HDAC2 3395/4885HDAC6 1517/4885 |
| US-20180354972-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | MYC, MYCBP, MYCBP2 | HDAC8 3242/4885HDAC2 4098/4885HDAC6 2305/4885 |
| US-10787444-B2 | Compounds for the modulation of myc activity | MYC, MYCBP, MYCBP2 | HDAC8 3405/4885HDAC2 3970/4885HDAC6 2251/4885 |
| US-11124527-B2 | Compounds for the modulation of Myc activity | MYC, MYCBP, MYCBP2 | HDAC8 3242/4885HDAC2 4098/4885HDAC6 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.